| 2025-12-05 |
详情>>
内部人交易：
Urist Marshall股份减少18242.00股
|
| 2025-11-05 |
详情>>
股本变动：
变动后总股本57723.81万股
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.29美元,归母净利润5.57亿美元,同比去年增长-14.45%
|
| 2025-11-05 |
财报披露：
美东时间 2025-11-05 盘前发布财报
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益0.63美元,归母净利润2.69亿美元,同比去年增长151.47%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益0.55美元,归母净利润2.38亿美元,同比去年增长4888.47%
|
| 2025-04-11 |
股东大会：
将于2025-05-12召开股东大会
会议内容 ▼▲
- 1.Vote to direct the chairman, if he determines that there are insufficient votes cast in favor of the Internalization Proposal, to adjourn the Annual Meeting to such time and place (which place may include electronic platforms) that he, in his absolute discretion, considers fit, to permit solicitation of additional votes (the “Adjournment Proposal”);
2.Vote on a proposal to (a) consummate the Purchase Agreement and each other agreement contemplated by the Purchase Agreement to be entered into in connection with the transactions contemplated by the Purchase Agreement (collectively, the “Transaction Documents”), (b) grant allotment authority for the issuance of (i) additional Class A ordinary shares of the Company sufficient to allow for the exchange by the Sellers of a number of class B ordinary shares of RPH equal to the Share Consideration and (ii) additional Class B ordinary shares of the Company in an amount equal to the Share Consideration, and (c) as contemplated by the Purchase Agreement and conditional upon separate consent of the holders of Class B ordinary shares, adopt amended articles of association of Royalty Pharma (the “Internalization Proposal”);
3.Approve, on a non-binding advisory basis, the compensation that may become payable to our named executive officers in connection with the Transaction (the “Say-on-Golden-Pay Proposal”);
4.Adopt the 2025 Equity Incentive Plan (the “EIP Proposal”);
5.Approve the terms of the agreements and counterparties pursuant to which we may purchase our Class A ordinary shares;
6.Approve the election of each of the nine director nominees of Royalty Pharma by separate ordinary resolutions;
7.Approve on a non-binding advisory basis the compensation of our named executive officers (the “Say-on-Pay Proposal”);
8.Ratify on a non-binding advisory basis the appointment of an independent registered public accounting firm;
9.Vote to receive the U.K. Annual Report and Accounts;
10.Approve on a binding basis our U.K. directors’ remuneration policy, included in the U.K. directors’ remuneration report contained in the U.K. Annual Report and Accounts (the “U.K. Directors’ Remuneration Policy”);
|
| 2025-02-12 |
详情>>
业绩披露：
2022年年报每股收益0.10美元,归母净利润4283.20万美元,同比去年增长-93.09%
|
| 2025-02-12 |
详情>>
业绩披露：
2024年年报每股收益1.92美元,归母净利润8.59亿美元,同比去年增长-24.31%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.45美元,归母净利润6.51亿美元,同比去年增长1.60%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益0.24美元,归母净利润1.07亿美元,同比去年增长-81.21%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益0.01美元,归母净利润477.80万美元,同比去年增长-98.6%
|
| 2024-04-25 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.Election of each of the eight director nominees listed in the accompanying Proxy Statement by separate ordinary resolutions.
2.Approve on a non-binding advisory basis the compensation of our named executive officers.
3.Ratify on a non-binding advisory basis the appointment of Ernst & Young LLP, as our independent registered public accounting firm.
4.Approve receipt of our U.K. Annual Report and Accounts for the fiscal year ended December 31, 2023.
5.Approve our U.K. directors' remuneration policy, included in the U.K. directors' remuneration report contained in the U.K. Annual Report and Accounts (the “U.K. Directors’ Remuneration Policy”).
6.Approve on a non-binding advisory basis our U.K. directors’ remuneration report in the U.K. Annual Report and Accounts (the “U.K. Directors’ Remuneration Report”).
7.Re-appoint Ernst & Young Chartered Accountants (“Ernst & Young”) as our U.K. statutory auditor under the U.K. Companies Act 2006 (the “U.K. Companies Act”), to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders.
8.Authorize the Board to determine the remuneration of our U.K. statutory auditor.
9.Authorize the Board to allot shares.
10.Authorize the Board to allot shares without rights of pre-emption.
|
| 2024-02-15 |
详情>>
业绩披露：
2023年年报每股收益2.54美元,归母净利润11.35亿美元,同比去年增长2549.50%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益1.43美元,归母净利润6.40亿美元,同比去年增长28.38%
|
| 2023-04-27 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.Election of each of the ten director nominees listed in the accompanying Proxy Statement by separate ordinary resolutions.
2.Approve on a non-binding advisory basis the compensation of our named executive officers.
3.Ratify on a non-binding advisory basis the appointment of Ernst & Young LLP, as our independent registered public accounting firm.
4.Approve receipt of our U.K. Annual Report and Accounts for the fiscal year ended December 31, 2022.
5.Approve on a non-binding advisory basis our U.K. directors’ remuneration report in the U.K. Annual Report and Accounts (the “U.K. Directors’ Remuneration Report”).
6.Re-appoint Ernst & Young Chartered Accountants (“Ernst & Young”) as our U.K. statutory auditor under the U.K. Companies Act 2006 (the “U.K. Companies Act”), to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders.
7.Authorize the board of directors to determine the remuneration of our U.K. statutory auditor.
|
| 2022-04-28 |
股东大会：
将于2022-06-23召开股东大会
会议内容 ▼▲
- 1.Election of each of the ten director nominees listed in the accompanying Proxy Statement by separate ordinary resolutions.
2.Approve on a non-binding advisory basis the compensation of our named executive officers.
3.Ratify on a non-binding advisory basis the appointment of Ernst & Young LLP, as our independent registered public accounting firm.
4.Approve receipt of our U.K. Annual Report and Accounts for the fiscal year ended December 31, 2021.
5.Approve on a non-binding advisory basis our U.K. directors’ remuneration report in the U.K. Annual Report and Accounts (the “U.K. Directors’ Remuneration Report”).
6.Re-appoint Ernst & Young Chartered Accountants (“Ernst & Young”) as our U.K. statutory auditor under the U.K. Companies Act 2006 (the “U.K. Companies Act”), to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders.
7.Authorize the board of directors to determine the remuneration of our U.K. statutory auditor.
8.Approve the terms of the agreements and counterparties pursuant to which we may purchase our Class A ordinary shares.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-24召开股东大会
会议内容 ▼▲
- 1.Election of each of the ten director nominees listed in the accompanying Proxy Statement by separate ordinary resolutions.
2.Approve on a non-binding advisory basis the compensation of our named executive officers.
3.Approve on a non-binding advisory basis the frequency of future non-binding advisory votes on the compensation of our named executive officers.
4.Ratify on a non-binding advisory basis the appointment of Ernst & Young Chartered Accountants (“Ernst & Young”), as our independent registered public accounting firm.
5.Approve receipt of our U.K. Annual Report and Accounts for the fiscal year ended December 31, 2020.
6.Approve our U.K. directors’ remuneration policy, included in the directors’ remuneration report contained in the U.K. Annual Report and Accounts (the “U.K. Directors’ Remuneration Policy”).
7.Approve on a non-binding advisory basis our U.K. directors’ remuneration report (excluding the U.K. Directors’ Remuneration Policy) in the U.K. Annual Report and Accounts (the “U.K. Directors’ Remuneration Report”).
8.Re-appoint Ernst & Young as our U.K. statutory auditor under the U.K. Companies Act 2006 (the “U.K. Companies Act”), to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders.
9.Authorize the board of directors to determine the remuneration of our U.K. statutory auditor.
|
| 2017-04-10 |
复牌提示：
2017-04-10 09:11:14 停牌，复牌日期 2017-04-10 09:50:00
|